AXDX Stock Overview
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Accelerate Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$11.90 |
| 52 Week Low | US$0.73 |
| Beta | 0.53 |
| 1 Month Change | -10.36% |
| 3 Month Change | -31.74% |
| 1 Year Change | -90.14% |
| 3 Year Change | -98.90% |
| 5 Year Change | -99.54% |
| Change since IPO | -44.54% |
Recent News & Updates
Recent updates
Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher
Apr 17
Accelerate Diagnostics spikes as Chief Technology Officer raises stake
Aug 30Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Aug 20Accelerate Diagnostics jumps 14% after beating Q2 estimates
Aug 15Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022
Mar 15Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022
Jan 04Accelerate Diagnostics: An Investment Assessment
Sep 07Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?
Feb 20
Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus
Jan 12Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years
Dec 29Shareholder Returns
| AXDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.8% | -2.9% | -3.2% |
| 1Y | -90.1% | -3.7% | 19.3% |
Return vs Industry: AXDX underperformed the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: AXDX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| AXDX volatility | |
|---|---|
| AXDX Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXDX's share price has been volatile over the past 3 months.
Volatility Over Time: AXDX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 134 | Jack Phillips | acceleratediagnostics.com |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Accelerate Diagnostics, Inc. Fundamentals Summary
| AXDX fundamental statistics | |
|---|---|
| Market cap | US$19.22m |
| Earnings (TTM) | -US$61.62m |
| Revenue (TTM) | US$12.06m |
1.6x
P/S Ratio-0.3x
P/E RatioIs AXDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXDX income statement (TTM) | |
|---|---|
| Revenue | US$12.06m |
| Cost of Revenue | US$9.51m |
| Gross Profit | US$2.55m |
| Other Expenses | US$64.17m |
| Earnings | -US$61.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 21.15% |
| Net Profit Margin | -510.97% |
| Debt/Equity Ratio | -185.2% |
How did AXDX perform over the long term?
See historical performance and comparison